Adipose- and Bone Marrow–Derived Mesenchymal Stem Cells Prolong Graft Survival in Vascularized Composite Allotransplantation
Authors:
- Jan A. PlockJPJan A. Plock
- Jonas T. SchniderJSJonas T. Schnider
- Wensheng ZhangWZWensheng Zhang
- Riccardo SchweizerRSRiccardo Schweizer
- Wakako TsujiWTWakako Tsuji
- Nataliya KosterevaNKNataliya Kostereva
- Paolo M. FanzioPFPaolo M. Fanzio
- Sudheer RavuriSRSudheer Ravuri
- Mario G. SolariMSMario G. Solari
- Hui-Yun ChengHCHui-Yun Cheng
- Peter J. RubinPRPeter J. Rubin
- Kacey G. MarraKMKacey G. Marra
- 1 September 2015
- journal article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 99 (9) , 1765-1773
Abstract
Strategies aiming at minimization or elimination of systemic immunosuppression are key immediate goals for clinical expansion of vascularized composite allotransplantation (VCA). We compared the in vitro and in vivo immunomodulatory efficacy of adipose-derived mesenchymal stem cells (AD-MSCs) and bone marrow (BM)-derived MSCs in a rat VCA model. Both cell types were tested in vitro for suppressor function using mixed lymphocyte reactivity assays. AD-MSCs or BM-MSCs were administered intravenously (1 × 10 or 5 × 10 cells/animal) to Lewis rat recipients of mismatched Brown Norway hindlimb transplants. Short course tacrolimus (FK-506) monotherapy was withdrawn at postoperative day 21. In vivo regulatory T-cell induction, peripheral blood chimerism, and microchimerism in lymphatic organs were analyzed. AD-MSCs and BM-MSCs exhibited strong dose-dependent suppressor function in vitro, which was significantly more pronounced for AD cells. In vivo, all animals revealed peripheral multi-lineage chimerism at four weeks (P < 0.01) independent of cell type and dosage. Regulatory T-cell levels were increased with both cell types, the most in AD-MSC groups. These immunomodulatory effects were only transient. MSC treatment resulted in long-term (>120 day) allograft survival in 47% of the animals, which correlated with durable microchimerism in BM and spleen. AD-MSCs and BM-MSCs exert immunomodulatory effects that prolong survival of immunogenic skin-bearing VCA grafts with short course (21 day) tacrolimus induction therapy. The in vivo findings in terms of allograft survival did not reflect superior immunomodulatory characteristics of AD-MSCs found in vitro.Keywords
This publication has 49 references indexed in Scilit:
- Facial transplantation: the first 9 yearsThe Lancet, 2014
- Adipose Tissue-Derived Multipotent Stromal Cells Have a Higher Immunomodulatory Capacity Than Their Bone Marrow-Derived CounterpartsStem Cells Translational Medicine, 2013
- Upper-Extremity Transplantation Using a Cell-Based Protocol to Minimize ImmunosuppressionAnnals of Surgery, 2013
- A Critical Analysis of Rejection in Vascularized Composite Allotransplantation: Clinical, Cellular and Molecular Aspects, Current Challenges, and Novel ConceptsFrontiers in Immunology, 2013
- Minimizing immunosuppression in hand transplantationExpert Review of Clinical Immunology, 2012
- On the interactions between mesenchymal stem cells and regulatory T cells for immunomodulation in transplantationFrontiers in Immunology, 2012
- Long-Term Follow-Up in Composite Tissue Allotransplantation: In-Depth Study of Five (Hand and Face) RecipientsAmerican Journal of Transplantation, 2011
- Mesenchymal Stem Cells as TherapeuticsAnnual Review of Biomedical Engineering, 2010
- Cotransplantation of HLA-Identical Sibling Culture-Expanded Mesenchymal Stem Cells and Hematopoietic Stem Cells in Hematologic Malignancy PatientsTransplantation and Cellular Therapy, 2005
- Comparison of Multi-Lineage Cells from Human Adipose Tissue and Bone MarrowCells Tissues Organs, 2003